---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-24-059544"
form_type: "8-K"
ticker: "ELVN"
cik: "0001672619"
company_name: "Enliven Therapeutics, Inc."
filed_at: "2024-05-14T23:59:59+00:00"
generated_at: "2026-06-02T00:56:58.640541+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Enliven Therapeutics Q1 net loss $22.7M; ELVN-001 Phase 1 shows 44% MMR at 12 weeks

## Summary
- Net loss of $22.7M for Q1 2024 vs $14.7M in Q1 2023; cash, equivalents & marketable securities $320.5M.
- ELVN-001 Phase 1 proof-of-concept: 44% (7/16) cumulative MMR rate by week 12 in response-evaluable CML patients.
- Entered $90M PIPE financing from new/existing investors; expected cash runway into late 2026.
- Appointed Dr. Lori Kunkel to Board of Directors.
- Activated first site for ELVN-002 combo trial with trastuzumab in HER2+ cancers; first dosing expected Q2 2024.

## SEC filing metadata
- accession: 0000950170-24-059544
- form_type: 8-K
- ticker: ELVN
- cik: 0001672619
- company_name: Enliven Therapeutics, Inc.
- filed_at: 2024-05-14T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1672619/000095017024059544/0000950170-24-059544-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1672619/000095017024059544/elvn-20240514.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-24-059544
- JSON: https://secwatch.observer/filing/0000950170-24-059544.json
- Plain text: https://secwatch.observer/filing/0000950170-24-059544.txt

## Key facts
- Earnings Releases
  Enliven Therapeutics, Inc. reported first quarter ended March 31, 2024 results: net income $22.7 million.
  - Period: first quarter ended March 31, 2024
  - Net income: $22.7 million
  - Result: reported results
  source text: Enliven Therapeutics Reports First Quarter Financial Results and Provides a Business Update
  evidence_url: https://www.sec.gov/Archives/edgar/data/1672619/000095017024059544/0000950170-24-059544-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.